Schedule a Meeting
Download Brochure
Table of Content
April 2025
Principal Consultant
Reviewed By
The global cell and gene therapy third-party logistics market size is calculated at US$ 10.75 in 2024, grew to US$ 11.94 billion in 2025, and is projected to reach around US$ 30.67 billion by 2034. The market is expanding at a CAGR of 11.09% between 2025 and 2034.
The emergence of the gene and cell therapy industries brings with it new demands on the supply chain. The distribution procedure for cell and gene therapy is a complicated system that calls for supply chain partners with specific skills to be highly visible and involved. An essential component of operationalizing cell and gene therapy (CAGT) studies is logistics management. In vivo and ex vivo gene treatments, gene editing, and autologous and allogeneic cell therapy techniques all have special logistical needs.
| Metric | Details |
| Market Size in 2024 | USD 10.75 Billion |
| Projected Market Size in 2034 | USD 30.67 Billion |
| CAGR (2025 - 2034) | 11.09% |
| Leading Region | North America |
| Market Segmentation | By Type, By Product, By Temperature Range, By Therapeutic Area, By End-use, By Region |
| Top Key Players |
Cencora Corporation, Cardinal Health, McKesson, Corporation, EVERSANA, Knipper Health, Arvato SE, DHL, FedEx, Kuehne + Nagel, United Parcel Service of America, Inc. |
Robotics and artificial intelligence (AI) are two of the most revolutionary technologies influencing 3PL logistics in the future. These technologies, which were originally thought of as future ideas, have swiftly evolved into vital instruments in the contemporary supply chain. They are incredibly useful tools for businesses trying to increase productivity, save expenses, and satisfy customers because of their capacity to automate, forecast, and optimize operations. AI helps logistics companies to improve every part of the supply chain, from inventory control to demand forecasting. AI helps companies allocate resources more effectively, minimizing excess inventory and preventing stockouts by spotting trends and forecasting changes in demand.
Rising Demand for Personalized Medicine
Unquestionably, cell and gene treatments represent a paradigm shift in personalized medicine. A new age in healthcare is being ushered in by the capacity to accurately target illnesses at the genetic and cellular levels, customize therapies to individual profiles, and maybe even cure disorders. The goal of highly individualized and successful medical treatments is coming true as research and innovation drive these medicines ahead, giving patients worldwide hope and better results. They have the power to transform healthcare results and be a lifesaver for future generations.
Cyber Threats and Data Security
The danger of cyberattacks and data breaches increases as logistical operations become more digitalized. Furthermore, safeguarding private data and preserving the integrity of digital systems are ongoing issues. Businesses must take steps to safeguard themselves against both internal and external cybersecurity risks, and they must teach staff members how to spot these dangers.
Globalization & Emerging Markets
Due to globalization and the development of companies into new regions, the cell and gene therapy third-party logistics market is expected to continue growing. There will be a greater need for dependable and effective logistics solutions as businesses want to expand globally. 3PL suppliers now have a great chance to broaden their skills and reach.
By type, the clinical segment dominated the cell and gene therapy third-party logistics market in 2024. For clinical trials to be conducted successfully, the clinical research supply chain is essential. It includes a complicated web of operations and parties engaged in the distribution, inventory control, logistics, and acquisition of necessary supplies for clinical research. In order to satisfy the demands of clinical trials, companies must have a streamlined and effective supply chain as the market for cutting-edge medical treatments and goods keeps expanding.
By type, the commercial segment is estimated to grow at the fastest CAGR in the cell and gene therapy third-party logistics market during the predicted time. Rapid approval processes for these cutting-edge medicines are the result of regulatory bodies all around the world realizing the therapeutic promise of gene and cell therapies. Strong cold chain logistics infrastructure is becoming more and more necessary as additional treatments are approved by regulators for commercialization in order to facilitate their distribution and patient delivery. The effective commercialization of gene and cell treatments creates new avenues for logistics firms to work with pharmaceutical businesses and healthcare providers, which propels the market's expansion.
By product, the cell therapies segment was dominant in the cell and gene therapy third-party logistics market in 2024. Healthcare is evolving due to the emergence of cell treatments. The growing availability of these medicines has given thousands of patients worldwide fresh hope for a favorable result from their illness. The main objective of cell therapy logistics is to protect samples at every stage before, during, and following transit in order to provide patients in need with efficient treatments.
By product, the gene therapies segment is expected to be the fastest growth rate in the cell and gene therapy third-party logistics market during 2025-2034. The supply chain difficulty is further exacerbated by the relative novelty of gene treatments. The majority of the usual requirements for a conventional drug may be met by a normal third-party logistics company with a pharmaceutical specialization. The criteria for gene therapies are even stricter, and these high-value, low-volume treatments require "white glove treatment." When making plans for these logistical requirements, a biopharma business should make use of specialist knowledge.
By temperature range, the ambient storage segment held the major cell and gene therapy third-party logistics market share in 2024. When it comes to the preservation and stability testing of biological materials, medicines, and other sensitive items that are impacted by temperature and humidity conditions, there are two different types of storage environments: ambient biological storage and stability storage. Increased shelf life, less spoiling and deterioration, and increased product quality and uniformity are just a few advantages of ambient storage.
By temperature range, the refrigerated storage segment is expected to be the fastest-growing in the cell and gene therapy third-party logistics market during the forecast period. A consistent, homogeneous temperature-controlled environment is necessary for cell and gene treatments. This is a result of the recent surge in specialized therapy invention and development. In order to maintain the proper temperature range for an extended amount of time until they reach the patient, many contemporary biologic treatments, including gene therapy, require a dependable infrastructure. The effectiveness, safety, and shelf life of these delicate medications are their main concerns, due to which cold/refrigerated storage is required.
By end-use, the biopharmaceutical companies segment led the cell and gene therapy third-party logistics market in 2024. Possessing adaptable specialist therapy skills for a range of novel therapeutics is one of the most significant new demands coming from biopharma businesses. Third-party logistics eliminates the difficulties involved in the distribution and logistics of pharmaceuticals, allowing biopharma businesses to concentrate on their core competencies. This raises the likelihood of increasing profitability and drastically lowers the pharmaceutical businesses' overhead.
By end-use, the CDMOs/CMOs segment is estimated to witness the fastest growth in the cell and gene therapy third-party logistics market during the forecast period. For a number of reasons, pharmaceutical firms have started to rely more on contract manufacturing organizations (CMOs) and pharma contract development and manufacturing organizations (CDMOs) over the last ten years. The collaboration has shown to be advantageous to both parties and a means of sharing risk with businesses that are better suited to manage it. This is due to the fact that CMOs possess the necessary operational experience, technological know-how, and increased capacity for taking risks.
North America dominated the cell and gene therapy third-party logistics market in 2024 because of the growing cell therapy production businesses and the growing efficacy of CGT supply chain services. Furthermore, the need for cell and gene therapies has grown significantly in the North American region in recent years as a result of increasing R&D spending and the number of clinical studies pertinent to the creation of goods based on cell and gene therapy.
An estimated 12,000 individuals in the United States will receive gene therapy or stem cell treatment in 2020, and by 2030, that number is predicted to rise to over 340 thousand. There have been other creative approaches put up to fund gene therapy treatments in addition to the current American system. CGT's approval pipeline keeps expanding. According to Evaluate, CGT accounted for 10% of all innovative approvals from the U.S. FDA in 2023, up from 7% and 6% in 2022 and 2021, respectively.
OmniaBio is receiving assistance from the Canadian government to expand its Hamilton, Ontario, plant in order to improve the production of cell and gene therapies. The project will merge robots and artificial intelligence (AI) for clinical and commercial-scale production, with an emphasis on enhanced therapies for chronic illnesses. In order to manufacture cell and gene treatments and offer manufacturing services to businesses worldwide, OmniaBio will expand its facilities at McMaster Innovation Park in Hamilton, Ontario, as part of this effort.
Asia Pacific is estimated to host the fastest-growing cell and gene therapy third-party logistics market during the forecast period. In terms of technological research, clinical trials, and product approvals, several Asia-Pacific nations have become desirable and important markets in the worldwide CGT industry, second only to the United States. Asia's most anticipated CGT knowledge-sharing conference, Cell & Gene Therapy World Asia 2025 (#CGTAsia2025), is back for its ninth year as the area becomes a global leader in regenerative medicine! The event, which aims to empower and connect stakeholders from the cell and gene therapy ecosystem, offers a unique opportunity to learn about the most recent developments in CAR-T technologies, gene therapies, and cell treatments.
In certain locations, China is testing a new wave of loosened restrictions on foreign investment, allowing foreign investment in gene and cell therapies as well as hospitals that are entirely controlled by foreigners. The action is a reflection of China's continuous attempts to expand its economy and draw in more international investment. The need for medical services is only increasing as China's population ages and its economy grows. China is an important market for international investors.
The market's expansion may be attributed to a number of reasons, including the development of gene delivery technologies, advanced medicines, increasing competition, and major manufacturers concentrating on commercializing their treatments. Developing a new gene editor with enhanced capabilities. These initiatives would facilitate the development of more attractive and financially viable treatments for the Indian populace by opening up possibilities for the gene editing application of locally produced goods.
Europe is expected to grow significantly in the cell and gene therapy third-party logistics market during the forecast period. In order to provide trustworthy and easily comprehensible information about the use of cells and genetic material to treat disease, 47 partner organizations and institutes from around Europe have joined forces to create the European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT). Leading cell and gene therapy research laboratories from around Europe are part of the collaboration, which also includes product developers, ethicists, attorneys, social scientists, patient advocates, and scientific communicators.
The use of gene and cell treatments is growing. The strategy paper for a National Strategy for Gene and Cell Therapies was sent to the German Federal Government on June 12, 2024. The goal of the paper is to provide a foundation for policymaking that will enable Germany to take the lead in Europe's gene and cell therapy (GCT) industry. The German government acknowledges that the era of GCTs has begun. However, research and development of GCTs in Germany are hampered by several legal, regulatory, and practical issues.
The advanced therapeutic sector is currently experiencing a critical juncture in its development. With the success of CAR-Ts, for instance, the proof of concept for these treatments has been proven. In the UK, 14 conditions had advanced therapies authorized and paid for as of March 2024. From £0.77 billion in the fiscal year ending in March 2023 to £0.97 billion in the fiscal year ending in March 2024, investment in the UK industry has also grown. This resurgence of development suggests that the industry is still seen as having promise.
In January 2024, Yaky Yanay, the president and CEO of Pluri, stated, "We anticipate that the opening of the CDMO division will increase cash flow and revenues by leveraging our established manufacturing facility and technology." The goal of PluriCDMOTM is to give our clients access to the best-in-class facilities and, more significantly, the essential expertise in cell therapy development that has been produced over the last 20 years. Being a premium boutique CDMO, PluriCDMO™ can help our partners build more quickly and better manage risks.
By Type
By Product
By Temperature Range
By Therapeutic Area
By End-use
By Region
April 2025
April 2025
April 2025
April 2025